source
- Oxford biotech OMass Therapeutics secures $310 million to advance genetic adrenal disorder programOxford-based OMass Therapeutics announced a $310 million private financing round, one of the largest recent fundraises for a UK biotech. The capital will fund the development of therapies targetin…
- OrbiMed secures $3 billion for new life science funds, with over $1 billion earmarked for AsiaOrbiMed, a leading global investor in life science companies, announced the closing of two new funds that together total about $3 billion. The capital will be deployed across a range of private equ…